Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Post by mstrmndon Jan 19, 2021 5:19pm
376 Views
Post# 32329519

ATB-346 for Ulcerative Colitis?

ATB-346 for Ulcerative Colitis?All longs, sorry been swaped with work, will pop in from time to time to drop my 2 cents

For diseases like Ulcerative Colitis, where ulcers in the large intestine are the core problem of the disease, the mucosal healing properties of the H2S pipeline are extremely exciting (this is why Phase 2a results are just simply incredible).

If you are able to reduce the inflammatory burden (NSAID component) and the hydrogen sulfide mediators confer additional mucosal protection (or healing), then 100% you have a very safe and likely to be well-tolerated treatment for Ulcerative Colitis. 

These diseases require immunosuppressives so if there were a non-immunosuppressive way to treat patients with mild to moderate disease, you would effectively change the paradigm of treatment.  No patient wants to be on immunosuppressives.  Generally NSAIDs are not used in Ulcerative Colitis or Crohn's for pain because it causes ulcers.  If ATB-346 heals the gastric mucosa for upper GI tract pathology could those same effects health the lower GI tract?  McWhirter has no idea what he's talking about when he speaks about "coating the stomach", it's not bismuth (pepto bismol), Otena does not provide topical healing, otherwise, ATB-346 supporitories and enemas for Ulcerative Colitis right away!  So if the effect is not topical, ATB-346 reduces systemic inflammation (NSAID) with massive GI (upper and lower GI tract) mucosal healing properties and is a non-immunosuppressive treatment in a 100% immunosuppressive world.  So there's your strategy to penetrate the market.  

Once amalgamation with Antibe Holding is complete, the first pop is market cap of combined entity.  This will be very interesting to see what happens.  Dan and co. (Echelon) better not screw this up with funny stuff, personally Dan should already be replaced imho, since he can't be trusted ever again to represent the interests of all shareholders.  He screwed shareholders in June by misleading shareholders to sell low.  Antibe is 100% manipulated and intentionally kept low to keep upside in their control.  However after watching this from almost IPO until now, the SP does not make any sense and its going to blow very soon.

Get in while you can because it's only going up and buyers are coming! 

GLTA!  
<< Previous
Bullboard Posts
Next >>